Article    Table of Contents                    Full Text of this article Free    PDF of this article    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search    Get Permissions  Google Scholar    Search for Related Content  Social Bookmarking

What's this?

PubMed

Articles in PubMed by Author:    Shapiro, R. L.    Swerdlow, D. L.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Botulism in the United States: A Clinical and Epidemiologic Review

Roger L. Shapiro, MD; Charles Hatheway, PhD; and David L. Swerdlow, MD

1 August 1998 | Volume 129 Issue 3 | Pages 221-228

Botulism is caused by a neurotoxin produced from the anaerobic, spore-forming bacterium Clostridium botulinum. Botulism in humans is usually caused by toxin types A, B, and E. Since 1973, a median of 24 cases of foodborne botulism, 3 cases of wound botulism, and 71 cases of infant botulism have been reported annually to the Centers for Disease Control and Prevention (CDC). New vehicles for transmission have emerged in recent decades, and wound botulism associated with black tar heroin has increased dramatically since 1994. Recently, the potential terrorist use of botulinum toxin has become an important concern.

Botulism is characterized by symmetric, descending, flaccid paralysis of motor and autonomic nerves, usually beginning with the cranial nerves.Blurred vision, dysphagia, and dysarthria are common initial complaints. The diagnosis of botulism is based on compatible clinical findings; history of exposure to suspect foods; and supportive ancillary testing to rule out other causes of neurologic dysfunction that mimic botulism, such as stroke, the Guillain-Barre syndrome, and myasthenia gravis. Laboratory confirmation of suspected cases is performed at the CDC and some state laboratories. Treatment includes supportive care and trivalent equine antitoxin, which reduces mortality if administered early. The CDC releases botulism antitoxin through an emergency distribution system. Although rare, botulism outbreaks are a public health emergency that require rapid recognition to prevent additional cases and to effectively treat patients. Because clinicians are the first to treat patients in any type of botulism outbreak, they must know how to recognize, diagnose, and treat this rare but potentially lethal disease.

Author and Article Information

From the Centers for Disease Control and Prevention, Atlanta, Georgia
(Hatheway) Deceased
Requests for Reprints: David L. Swerdlow, MD, Centers for Disease Control and Prevention, 1600 Clifton Road, MS A-38, Atlanta, GA 30333.
Current Author Addresses: Drs. Shapiro and Swerdlow: Centers for Disease Control and Prevention, 1600 Clifton Road, MS A-38, Atlanta, GA 30333.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

This article has been cited by other articles:

				R. M. Domingo, J. S. Haller, and M. Gruenthal Infant Botulism: Two Recent Cases and Literature Review J Child Neurol, November 1, 2008; 23(11): 1336 - 1346. [Abstract] [PDF]

				F. H. Al-Saleem, D. M. Ancharski, E. Ravichandran, S. G. Joshi, A. K. Singh, Y. Gong, and L. L. Simpson The Role of Systemic Handling in the Pathophysiologic Actions of Botulinum Toxin J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 856 - 863. [Abstract] [Full Text] [PDF]

				J. E. Keller Characterization of New Formalin-Detoxified Botulinum Neurotoxin Toxoids Clin. Vaccine Immunol., September 1, 2008; 15(9): 1374 - 1379. [Abstract] [Full Text] [PDF]

				Z. F. Dembek, L. A. Smith, and J. M. Rusnak Botulism: Cause, Effects, Diagnosis, Clinical and Laboratory Identification, and Treatment Modalities Disaster Med Public Health Preparedness, November 1, 2007; 1(2): 122 - 134. [Abstract] [Full Text] [PDF]

				I. Artin, P. Bjorkman, J. Cronqvist, P. Radstrom, and E. Holst First Case of Type E Wound Botulism Diagnosed Using Real-Time PCR J. Clin. Microbiol., November 1, 2007; 45(11): 3589 - 3594. [Abstract] [Full Text] [PDF]

				S. Chen and J. T. Barbieri Multiple Pocket Recognition of SNAP25 by Botulinum Neurotoxin Serotype E J. Biol. Chem., August 31, 2007; 282(35): 25540 - 25547. [Abstract] [Full Text] [PDF]

				A. Fischer and M. Montal Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes PNAS, June 19, 2007; 104(25): 10447 - 10452. [Abstract] [Full Text] [PDF]

				S. Chen, J.-J. P. Kim, and J. T. Barbieri Mechanism of Substrate Recognition by Botulinum Neurotoxin Serotype A J. Biol. Chem., March 30, 2007; 282(13): 9621 - 9627. [Abstract] [Full Text] [PDF]

				F. Cai, C. B. Adrion, and J. E. Keller Comparison of extracellular and intracellular potency of botulinum neurotoxins. Infect. Immun., October 1, 2006; 74(10): 5617 - 5624. [Abstract] [Full Text] [PDF]

				M. Cengiz, M. Yilmaz, L. Dosemeci, and A. Ramazanoglu A botulism outbreak from roasted canned mushrooms Human and Experimental Toxicology, May 1, 2006; 25(5): 273 - 278. [Abstract] [PDF]

				S. Chen and J. T. Barbieri Unique Substrate Recognition by Botulinum Neurotoxins Serotypes A and E J. Biol. Chem., April 21, 2006; 281(16): 10906 - 10911. [Abstract] [Full Text] [PDF]

				A. Gupta, C. J. Sumner, M. Castor, S. Maslanka, and J. Sobel Adult botulism type F in the United States, 1981-2002 Neurology, December 13, 2005; 65(11): 1694 - 1700. [Abstract] [Full Text] [PDF]

				R. Keto-Timonen, M. Nevas, and H. Korkeala Efficient DNA Fingerprinting of Clostridium botulinum Types A, B, E, and F by Amplified Fragment Length Polymorphism Analysis Appl. Envir. Microbiol., March 1, 2005; 71(3): 1148 - 1154. [Abstract] [Full Text] [PDF]

				M. Nevas, M. Lindstrom, S. Hielm, K. J. Bjorkroth, M. W. Peck, and H. Korkeala Diversity of Proteolytic Clostridium botulinum Strains, Determined by a Pulsed-Field Gel Electrophoresis Approach Appl. Envir. Microbiol., March 1, 2005; 71(3): 1311 - 1317. [Abstract] [Full Text] [PDF]

				E. van Lunteren, M. Moyer, and H. J. Kaminski Adverse effects of myasthenia gravis on rat phrenic diaphragm contractile performance J Appl Physiol, September 1, 2004; 97(3): 895 - 901. [Abstract] [Full Text] [PDF]

				K. Inoue, M. Sobhany, T. R. Transue, K. Oguma, L. C. Pedersen, and M. Negishi Structural analysis by X-ray crystallography and calorimetry of a haemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum Microbiology, December 1, 2003; 149(12): 3361 - 3370. [Abstract] [Full Text] [PDF]

				M J P Biggs and C A Quick Mysterious dysphagia J R Soc Med, November 1, 2003; 96(11): 549 - 550. [Full Text] [PDF]

				Outbreak of Botulism Type E Associated With Eating a Beached Whale--Western Alaska, July 2002 JAMA, February 19, 2003; 289(7): 836 - 838. [Full Text] [PDF]

				C. O. Martin and H. P. Adams Jr Neurological Aspects of Biological and Chemical Terrorism: A Review for Neurologists Arch Neurol, January 1, 2003; 60(1): 21 - 25. [Abstract] [Full Text] [PDF]

				R. F Robinson and M. C Nahata Management of Botulism Ann. Pharmacother., January 1, 2003; 37(1): 127 - 131. [Abstract] [Full Text] [PDF]

				B. A. Racette, G. Lopate, L. Good, S. Sagitto, and J. S. Perlmutter Ptosis as a remote effect of therapeutic botulinum toxin B injection Neurology, November 12, 2002; 59(9): 1445 - 1447. [Abstract] [Full Text] [PDF]

				P. E. Marik and S. Bowles Analytic Reviews: Management of Patients Exposed to Biological and Chemical Warfare Agents J Intensive Care Med, July 1, 2002; 17(4): 147 - 161. [Abstract] [PDF]

				S. M. Harvey, J. Sturgeon, and D. E. Dassey Botulism Due to Clostridium baratii Type F Toxin J. Clin. Microbiol., June 1, 2002; 40(6): 2260 - 2262. [Abstract] [Full Text] [PDF]

				C. E. Sandrock and S. Murin Clinical Predictors of Respiratory Failure and Long-term Outcome in Black Tar Heroin-Associated Wound Botulism Chest, August 1, 2001; 120(2): 562 - 566. [Abstract] [Full Text] [PDF]

				S. S. Arnon, R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, J. Hauer, M. Layton, et al. Botulinum Toxin as a Biological Weapon: Medical and Public Health Management JAMA, February 28, 2001; 285(8): 1059 - 1070. [Abstract] [Full Text] [PDF]

				E. Weir Botulism in Canada Can. Med. Assoc. J., February 1, 2001; 164(4): 538 - 538. [Full Text] [PDF]

				M. A. Keller and E. R. Stiehm Passive Immunity in Prevention and Treatment of Infectious Diseases Clin. Microbiol. Rev., October 1, 2000; 13(4): 602 - 614. [Abstract] [Full Text] [PDF]

				R. H. Sandler, S. M. Finegold, E. R. Bolte, C. P. Buchanan, A. P. Maxwell, M.-L. Vaisanen, M. N. Nelson, and H. M. Wexler Short-Term Benefit From Oral Vancomycin Treatment of Regressive-Onset Autism J Child Neurol, July 1, 2000; 15(7): 429 - 435. [Abstract] [PDF]

				R. G. Villar, R. L. Shapiro, S. Busto, C. Riva-Posse, G. Verdejo, M. I. Farace, F. Rosetti, J. A. San Juan, C. M. Julia, J. Becher, et al. Outbreak of Type A Botulism and Development of a Botulism Surveillance and Antitoxin Release System in Argentina JAMA, April 14, 1999; 281(14): 1334 - 1340. [Abstract] [Full Text] [PDF]